Biotage AB (publ)

As of March 31, 2025, Biotage AB (publ) has 80.05M shares outstanding.

As of March 31, 2025, Biotage AB (publ) trades at a trailing price-to-earnings ratio of 29.91. The price-to-sales ratio is 3.90, and the price-to-book ratio stands at 4.63.

As of March 31, 2025, Biotage AB (publ) trades at an EV/EBITDA multiple of 24.50 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 3.81 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 24.50 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Biotage AB (publ) trades at an EV/FCF ratio of 14.71, comparing the total takeover cost of the business to the cash it actually generates for all capital providers.

As of March 31, 2025, Biotage AB (publ) maintains a current ratio of 2.53, meaning it holds 2.5x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended March 31, 2025, Biotage AB (publ) posted a return on equity (ROE) of 16.12, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 6.41 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 5.20, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 13.42, useful for judging operating efficiency across full business cycles. Inventory turnover of 1.66 indicates how many times Biotage AB (publ) sells and replaces its inventory over a year, a key working capital efficiency ratio.

These figures cover the twelve months ended March 31, 2025. That works out to an effective tax rate of 12.03, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items.

As of the close on July 21, 2025, Biotage AB (publ)'s stock has declined approximately 22.72% over the past 52 weeks. The 50-day moving average sits at 142.41, while the 200-day moving average is 141.07.

Over the twelve months ended March 31, 2025, Biotage AB (publ) posted a gross margin of 62.67, reflecting its pricing power and cost economics. The operating margin of 15.55 and net profit margin of 13.05 provide insight into operational efficiency.

These figures cover the twelve months ended March 31, 2025. The dividend payout ratio of 50.00 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 6.63, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 2.06, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Biotage AB (publ) shareholders.

As of March 31, 2025, Biotage AB (publ) has an Altman Z-Score of 9.10, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.